2020
DOI: 10.1007/s10973-020-09340-4
|View full text |Cite
|
Sign up to set email alerts
|

Solid-state compatibility studies of Ketoconazole-Fumaric acid co-crystal with tablet excipients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 31 publications
0
13
0
Order By: Relevance
“…31 Hz, 2H). 13 Synthesis of N-(5-Bromopyridin-2-yl)benzamide. 2-Amino-5bromopyridine (1.90 g, 11.0 mmol) was dissolved in 50 mL of pyridine and cooled in an ice bath.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%
See 1 more Smart Citation
“…31 Hz, 2H). 13 Synthesis of N-(5-Bromopyridin-2-yl)benzamide. 2-Amino-5bromopyridine (1.90 g, 11.0 mmol) was dissolved in 50 mL of pyridine and cooled in an ice bath.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%
“…1 H NMR (400 MHz, DMSO-d 6 ): δ 10.53 (s, 1H), 8.76 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.46 (dd, J = 2.6, 0.7 Hz, 1H), 8.31 (dd, J = 8.9, 0.7 Hz, 1H), 8.22 (dt, J = 7.8, 1.1 Hz, 1H), 8.12 (td, J = 7.7, 1.7 Hz, 1H), 8.04 (dd, J = 8.9, 2.6 Hz, 1H), 7.74 (ddd, J = 7.6, 4.8, 1.3 Hz, 1H). 13 Synthesis of N-(5-Bromopyridin-2-yl)picolinamide. Picolinic acid (1.00 g, 8.13 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (4.00 g, 10.5 mmol), triethylamine (3.40 mL, 24.4 mmol), and 2-amino-5-bromopyridine (1.54 g, 8.90 mmol) were dissolved in 60 mL of DMF.…”
Section: ■ Experimental Sectionmentioning
confidence: 99%
“…DSC takes the first preference for rapid analysis of incompatibility of the pharmaceutical mixture Thus, in this current research DSC (SDT.Q600, USA) is a thermoanalytical method used to study interaction between active drug and excipients. The pure drug,superdisintegrants, and its mixtures were scanned individually to confirm compatibility [20,21].…”
Section: Dsc Studymentioning
confidence: 99%
“…The efficiency, safety, quality, and stability of pharmaceutical dosage forms, which are the result of the active pharmaceutical ingredients (API) combination with excipients, are of major importance in the drug development process. A proper formulation design involves the selection of suitable excipients; although these pharmacologically-inactive substances are considered inert molecules, during the formulation stage and/or under storage of final product, interactions may occur even in solid state, leading to a diminution of concentration of API [ 32 , 33 , 34 ]. Potential interactions between an API and excipients have to be evaluated because the incompatibilities between the components of a dosage form can affect the bioavailability, stability, potency, and safety of drug products [ 35 , 36 ].…”
Section: Introductionmentioning
confidence: 99%